#275 A good sleep would be dop(aminergic) doc! Pramipexole in restless legs syndrome
CLINICAL QUESTION
Is pramipexole effective for the treatment of restless legs syndrome (RLS)?
BOTTOM LINE
Systematic review of twelve randomized controlled trials demonstrates 63% of patients using pramipexole report feeling much or very much better compared to 41% on placebo over 3-26 weeks. Lower doses (example 0.25/0.5mg) may have equivalent efficacy to higher doses with less risk of augmentation (paradoxical worsening of symptoms with treatment), although up to ~40% of patients may experience augmentation after 1 year.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Systematic review 12 randomized, controlled trials (RCTs), 3286 patients, average age 49-58 years, pramipexole 0.125 - 1.5mg/d versus placebo for 3 - 26 weeks.1
- Pramipexole significantly increased proportion of patients reporting:
- Improved symptoms (“very much better” or “much better”):
- 63% versus 41%; number needed to treat (NNT)=5.
- ≥50% reduction in International Restless Leg Score (IRLS):
- 62% versus 38%, NNT=5.
- Improved symptoms (“very much better” or “much better”):
- Multiple outcomes assessed.2-6
- Patient Global Impression Improvement (“much or very much better”) at 3-6 weeks with:2,4
- 0.25mg: 73%,
- 0.5mg: 77-79%,
- 0.75mg: 57%-68%.
- Patient Global Impression Improvement (“much or very much better”) at 3-6 weeks with:2,4
- Meta-analyzed by PEER, statistically significant increase versus placebo at 3-26 weeks for:
- Nausea: 8 RCTs, 2050 patients:2,7-13
- Pramipexole 14% versus placebo 5%, number needed to harm (NNH)=13.
- Fatigue: 6 RCTs, 1596 patients:2,7,8,10,11,13
- Pramipexole 10% versus placebo 6%, NNH=23.
- No statistically significant increase in dizziness, somnolence or headache compared to placebo.
- Nausea: 8 RCTs, 2050 patients:2,7-13
- Non-pharmacologic treatment options should be tried first. Limited evidence supports options such as exercise, standard acupuncture, and compression devices.14
- If ferritin <50-75ug/L, iron supplementation may be beneficial.15,16
- Other dopaminergic drugs (example ropinirole) have demonstrated similar efficacy.15
- Augmentation may be difficult to identify (example a patient stable for 6 months asks for more medication).16 Risk increases with higher doses of pramipexole16 and duration of treatment:16-18
- <1 year: up to 8%,
- ≥1 year: up to 42%.
- Management of augmentation includes: Modified dosing (example split or earlier dose), alternate pharmacotherapies (example pregabalin or gabapentin), and minimizing exacerbating drugs (examples antihistamines, dopamine-receptor blockers, or serotonergic antidepressants).3,16
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
I would be curious to know if there is an additive effect affect with gabapentin/pregabalin. I do have the odd patient who fails pramipexole and has a normal ferritin and magnesium level, and have wondered about adding second-line medications in such cases.
pramipexole reasonably effective for restless leg syndrome